secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104434
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion appeals NYSE delisting; trading moves to OTC; FDA approval of balloon catalyst for relisting plan
--------------------------------------------------------------------------------

- NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.
- Trading suspended after March 6, 2026; common stock and warrants now trade on OTCID Market under ALUR and ALUR.WS.
- Company appealed delisting determination and will attempt to regain compliance with NYSE or list on NYSE American.
- FDA approval of Allurion Gastric Balloon System (Feb 20, 2026) catalyzed plan to strengthen balance sheet and fund U.S. commercialization.
- CEO Dr. Shantanu Gaur expressed confidence in executing the plan to treat obesity in over 100M Americans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000119312526104434/0001193125-26-104434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000119312526104434/alur-20260306.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer